Vivo Opportunity Fund Holdings, L.P. and affiliated entities filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership positions in SAB Biotherapeutics, Inc. as of September 30, 2026.
Key Highlights
- Triggering event date: The filing reports a date of event of September 30, 2026.
- Vivo Opportunity Fund Holdings stake: The Delaware-organized fund reports aggregate beneficial ownership of 22,287,501 shares, equal to 9.99% of the class.
- Vivo Opportunity Cayman Fund stake: The Cayman Islands-organized fund reports aggregate beneficial ownership of 2,251,010 shares, also equal to 9.99% of the class.
- Direct common stock held: Vivo Opportunity Fund Holdings holds 6,282,901 shares of common stock outright; Vivo Opportunity Cayman Fund holds 632,110 shares outright.
- Warrant and preferred stock components: The aggregate totals include shares issuable via Enrollment Warrants and Data Release Warrants, each exercisable into Series B Preferred Stock convertible into common stock within 60 days.
- Blocking provisions apply: According to the filing, the Series B Preferred Stock, Enrollment Warrants, and Data Release Warrants each contain provisions preventing conversion or exercise that would result in the holder or its affiliates exceeding 9.99% of the issuer's voting securities.
- General partners: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
Vivo Opportunity Entities Detail Multi-Component Holdings in SAB Biotherapeutics
According to the filing, Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership, reports sole voting and dispositive power over 22,287,501 shares of SAB Biotherapeutics, Inc. common stock (CUSIP 78397T202). The filing states this aggregate is composed of four elements: 6,282,901 shares of common stock held directly; 446,000 shares issuable upon conversion of 4,460 shares of Series B Preferred Stock within 60 days; 10,372,400 shares issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants exercisable within 60 days; and 5,186,200 shares issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants exercisable within 60 days.
Vivo Opportunity Cayman Fund, L.P., organized in the Cayman Islands, separately reports sole voting and dispositive power over 2,251,010 shares, comprising 632,110 shares of common stock held directly; 47,500 shares issuable upon conversion of 475 shares of Series B Preferred Stock; 1,047,600 shares issuable from 10,476 Enrollment Warrants; and 523,800 shares issuable from 5,238 Data Release Warrants. Each of the two general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, reports identical beneficial ownership figures to its respective fund.
The filing notes that "the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions." All securities held by Vivo Opportunity Fund Holdings are stated to be held of record by that entity; all securities attributed to the Cayman fund are held of record by Vivo Opportunity Cayman Fund, L.P.
What Was Disclosed
Four Vivo-affiliated entities filed Amendment No. 2 to Schedule 13G disclosing beneficial ownership in SAB Biotherapeutics, Inc. as of September 30, 2026, with each entity reporting a 9.99% ownership position in the issuer's common stock (CUSIP 78397T202).






Please wait processing your request...